Aseptix develops, patents and markets novel antimicrobial and disinfection technologies. These technologies are licensed out to global market leaders across various industries, ranging from professional (healthcare, food, leisure, beverages, institutional, etc.) to consumer (household) and personal care. The technologies differentiate against traditional antimicrobials by combining fast anti-microbial activity and low-tox profile, with high user-safety.

We have an ambitious approach to eradicate environmentally burdening and user-unsafe antimicrobials, while delivering technologies that can help make our world safer, by lowering infection risks, and reducing outbreaks.

 We drive our industry to improved safety and sustainability
Aseptix is on a continuous quest to improve safety and sustainability. Safety by eradicating resistant and pathogenic organisms, avoiding infections to spread, but also safety in use for patients, users and consumers. We are committed to provide an alternative to unsafe and burdening chemicals that are the standard in our industry. We focus on sustainable solutions and sustainable delivery mechanisms to improve quality of living for generations to come.

We move the bar and set a new standard in safer infection control.

Our Mission

The Aseptix mission is to be a trusted innovation partner for our clients in antimicrobial technologies. We prove that fighting microbes does not mean unnecessarily burdening our planet or future generations. We strive to be a global leader in next generation “worry free” antimicrobials for consumers and professionals, excelling in quality, safety and performance.

Our Vision

To become the global alternative replacing user unsafe and environmentally burdening antimicrobials. To enable a world in which future sustainability and current protection against microbes are well balanced.



Aseptix Health Sciences NV was founded in 2005 with a corporate mission to become the global alternative for user unsafe and environmentally burdening antimicrobials and to build this into numerous applications.

Today, we are a rapidly growing company with an extensive portfolio of over 60 patents for technologies intended to prevent infectious diseases and the spread of pathogens. We provide the world’s fastest acting disinfectants with the broadest spectrum of kill optimized for use in key applications.

The beginning years of the development have been solely focused on research and development, together with academia and institutes. Aseptix invented several technologies, among others we are the inventors of Plasma Enhanced Hydrogen Peroxide® and Hi-Speed Hydrogen Peroxide®.

With Plasma Enhanced Hydrogen Peroxide®, a solution of hydrogen peroxide is subjected to a proprietary cold glow discharge plasma process, producing a highly active hydrogen peroxide solution. Aseptix patented both the processes, as well as the products formed by subjecting hydrogen peroxide to a gas plasma process.


Enhanced or Hi-Speed Hydrogen Peroxide® is an invention whereby standard hydrogen peroxide is synergistically combined with very specific compounds that have no or very little antimicrobial effect in itself. When combined with hydrogen peroxide a remarkable synergy is observed, which results in a much faster antimicrobial effect and a highly

stable product. Aseptix patented a range of these combinations, for use in surface disinfection, skin antimicrobials, skin and hands disinfection, mucous membrane disinfection, etc

After years of core research and development, Aseptix signed its first license agreement with SSL (now Reckitt Benckiser) in 2008 for use of its technologies in Scholl foot care products. In the same year, Aseptix signed an agreement with Beiersdorff for use in Hand Wipes, and with Rentokil Initial for several disinfection products.


In 2009, Aseptix launched its own line of professional disinfectants in the European hospital market, starting with France and Germany. We also signed an agreement with Georgia Pacific (now Essity) for development and supply of innovative disinfecting hand soaps and hand sanitizers.

In 2010, Aseptix also launched in the pharmaceutical cleanroom market in Europe.Today, the Aseptix brand products have become a new standard in healthcare and pharmaceutical cleanrooms in various European countries and India. Many well-known pharmaceutical companies, as well as many (academic) hospitals and long term care facilities have switched over to the Aseptix products

In 2011, Aseptix signs on OEM agreements with Oriola of Finland, Aurium of Canada, and Bouty of Italy for its feet deodorization line. It furthermore expands the Aseptix own brand distribution into India and the Nordic area.

In 2012, Aseptix announced a large license agreement with The Clorox Company and the launch of the Aseptix-based products on the American healthcare market. First large clients are signed on in Norway, Sweden and India.

In 2013, Aseptix wins 5 large pharmaceutical companies as client, adds a total of 12 hospitals, of which 4 academic hospitals in The Netherlands, Germany, Switzerland and France, often winning from large, incumbent infection prevention specialist suppliers, and the total client number across Europe exceeds 200

In 2014, Aseptix signs a large license agreement with Ecolab, a global leader in cleaning, food safety, sanitization and disinfection, listed on the New York Stock Exchange (ECL). Ecolab also acquired the European business from Aseptix.

In 2015, Aseptix and Dutch consumer brand Blue Wonder sign a license for patented surface cleaning and disinfection products. These products are available in all major supermarkets in the Netherlands.

In 2016, Aseptix expands its business with Essity to launch novel hand sanitizers for food, healthcare and sanitary environments.

In 2018, Clorox relaunches its Aseptix-based product line and continues the rapid growth path.

Worry Free Antimicrobials

top of page